BMS Iberdomide Shows Promising MRD Results in Phase III Multiple Myeloma Trial

Bristol Myers Squibb (BMS) reported that its investigational cereblon E3 ligase modulator, iberdomide, achieved a successful minimal residual disease (MRD) endpoint in a mid-stage analysis of the Phase III EXCALIBER-RRMM trial (NCT04975997) for relapsed or refractory multiple myeloma (r/r MM). The study evaluates iberdomide in combination with standard-of-care therapies, Darzalex (daratumumab) and dexamethasone. Interim results showed a statistically significant improvement in MRD negativity rates compared to the control arm, supporting the continued evaluation of dual-primary endpoints including progression-free survival (PFS) and secondary endpoints such as overall survival (OS) and safety. The combination’s safety profile remains consistent with previous studies. Iberdomide, the first in a novel CELMoD class, may form a new foundation for MM treatment, potentially combined with other therapies. Following these findings, BMS plans discussions with regulators, leveraging the FDA’s 2024 support for MRD as an intermediate endpoint for accelerated approvals.

27-09-2025